The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects

被引：40

作者：

Vettor, Roberto ^{[1
]}

Inzucchi, Silvio E. ^{[2
]}

Fioretto, Paola ^{[1
]}

机构：

[1] Univ Padua, Dept Med, Internal Med 3, Via Giustiniani 2, I-35128 Padua, Italy

[2] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA

来源：

DIABETOLOGIA | 2017年 / 60卷 / 03期

关键词：

Cardiovascular disease; Empagliflozin; Heart failure; Mitochondrial function; NHE; SGLT2; inhibitors; Type; 2; diabetes; HEART-FAILURE; MITOCHONDRIAL BIOGENESIS; OUTCOMES; RISK; ADAPTATION; INHIBITORS; MECHANISMS;

D O I：

10.1007/s00125-016-4194-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：395 / 398

页数：4

共 22 条

[1] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study [J].

Abdul-Ghani, Muhammad ;

Del Prato, Stefano ;

Chilton, Robert ;

DeFronzo, Ralph A. .

DIABETES CARE, 2016, 39 (05) :717-725

[2] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].

Baartscheer, Antonius ;

Schumacher, Cees A. ;

Wust, Rob C. I. ;

Fiolet, Jan W. T. ;

Stienen, Ger J. M. ;

Coronel, Ruben ;

Zuurbier, Coert J. .

DIABETOLOGIA, 2017, 60 (03) :568-573

[3] Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy [J].

Cingolani, Horacio E. ;

Ennis, Irene L. .

CIRCULATION, 2007, 115 (09) :1090-1100

[4] Cardiac Metabolism in Heart Failure Implications Beyond ATP Production [J].

Doenst, Torsten ;

Tien Dung Nguyen ;

Abel, E. Dale .

CIRCULATION RESEARCH, 2013, 113 (06) :709-724

[5] CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis [J].

Ferrannini, Ele ;

Mark, Michael ;

Mayoux, Eric .

DIABETES CARE, 2016, 39 (07) :1108-1114

[6] Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients [J].

Ferrannini, Ele ;

Muscelli, Elza ;

Frascerra, Silvia ;

Baldi, Simona ;

Mari, Andrea ;

Heise, Tim ;

Broedl, Uli C. ;

Woerle, Hans-Juergen .

JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (02) :499-508

[7] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial [J].

Fitchett, David ;

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Hantel, Stefan ;

Salsali, Afshin ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. ;

Lienart, F. ;

Mortelmans, J. .

EUROPEAN HEART JOURNAL, 2016, 37 (19) :1526-1534

[8] The ups and downs of mitochondrial calcium signalling in the heart [J].

Griffiths, Elinor J. ;

Balaska, Dirki ;

Cheng, Wendy N. Y. .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2010, 1797 (6-7) :856-864

[9] Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications [J].

Heerspink, Hiddo J. L. ;

Perkins, Bruce A. ;

Fitchett, David H. ;

Husain, Mansoor ;

Cherney, David Z. I. .

CIRCULATION, 2016, 134 (10) :752-772

[10] Intracellular Na+ Concentration ([Na+]i) Is Elevated in Diabetic Hearts Due to Enhanced Na+-Glucose Cotransport [J].

Lambert, Rebekah ;

Srodulski, Sarah ;

Peng, Xiaoli ;

Margulies, Kenneth B. ;

Despa, Florin ;

Despa, Sanda .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (09)

← 1 2 3 →